Day One Biopharmaceuticals, Inc.

This early-stage trial is testing a new targeted cancer drug called DAY301 in people with advanced or spreading solid tumors. The study will first find the safest dose and then see if the drug can shrink tumors in cancers like ovarian, lung, breast, and others. About 254 patients…

This study is testing a new oral drug called tovorafenib (DAY101) against standard chemotherapy for children and young adults with a specific type of slow-growing brain tumor. The goal is to see if the new drug is more effective at shrinking tumors and controlling the disease, an…